VIVS
What one share of VivoSim Labs holds
Biological Products, (No Diagnostic Substances)
VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine.
VivoSim Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.77 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.09 |
| Cash and investments | $0.52 |
| Book value | −$0.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.87 | −$7.87 | $0.28 | −$6.25 | — | $11.93 |
| 2018 | $0.86 | −$6.49 | $0.04 | −$5.42 | — | $8.03 |
| 2019 | $0.54 | −$4.62 | $0.01 | −$3.55 | — | $5.85 |
| 2020 | $0.34 | −$2.80 | $0.00 | −$2.30 | — | $4.08 |
| 2021 | $0.00 | −$2.44 | $0.06 | −$1.99 | — | $4.52 |
| 2022 | $0.17 | −$1.32 | $0.05 | −$1.02 | — | $3.47 |
| 2023 | $0.04 | −$1.98 | $0.05 | −$1.47 | — | $1.76 |
| 2024 | $0.14 | −$19.25 | $0.06 | −$19.28 | — | $4.29 |
| 2025 | $0.10 | −$1.70 | $0.01 | −$6.47 | — | $5.53 |
| 2026 | $0.05 | −$5.35 | $0.00 | −$4.18 | — | −$0.38 |